Serum 25OHD concentration as a predictor of haemoglobin A1c among adults living in the USA: NHANES 2003 to 2010

Michele Nicolo ,¹ Joseph I Boullata²

¹Keck School of Medicine, University of Southern California, Los Angeles, California, USA
²Nutrition Sciences, Drexel University, Philadelphia, Pennsylvania, USA

Correspondence to

Dr Michele Nicolo, University of Southern California, Los Angeles, CA 90007, USA; mnicolo@usc.edu

Received 7 March 2019

Revised 25 April 2019

Accepted 10 May 2019

Published Online First

10 June 2019

ABSTRACT

Background Vitamin D status influences glucose metabolism. Serum 25-hydroxyvitamin D (25OHD) concentrations have been inversely associated with type 2 diabetes risk. The optimal serum 25OHD level needed for adequate glycaemic control is unknown.

Objective To determine the relationship among serum 25OHD concentrations and degree of glucose regulation using percentage of haemoglobin A1c (HbA1c%).

Methods Data for adults ≥ 20 years from the National Health and Nutrition Examination Survey (NHANES) (2003–2010) were included. A binary logistic regression was used for serum 25OHD (nmol/L) as a continuous variable to determine the OR and 95% CI for HbA1c $> 6.5\%$, adjusting for sex, race and body mass index (BMI). Measures of serum 25OHD were grouped into quartiles and entered into a binary logistic regression model to determine the OR and 95% CI for HbA1c $> 6.5\%$ in an adjusted model.

Results Across all NHANES cycles, lower serum 25OHD was associated with greater odds of HbA1c $\geq 6.5\%$ when adjusting for sex, race, age and BMI (NHANES 2003–2004 (N=4402): OR 0.985, 95% CI 0.979 to 0.990; NHANES 2005–2006 (N=4409): OR 0.976, 95% CI 0.969 to 0.982; NHANES 2007–2008 (N=4525): OR 0.989, 95% CI 0.984 to 0.993; and NHANES 2009–2010 (N=5660): OR 0.988, 95% CI 0.984 to 0.991). In an adjusted model, the lowest quartile of serum 25OHD (0–41 nmol/L, N=4879) was associated with greater odds of HbA1c $\geq 6.5\%$ compared with the highest quartile (73–260 nmol/L, N=4472), OR 2.37, 95% CI 2.03 to 2.77. The odds of HbA1c $\geq 6.5\%$ were also greater for adults with serum 25OHD considered to be sufficient compared with the highest quartile, OR 1.68, 95% CI 1.56 to 1.61).

Conclusion Lower serum 25OHD concentrations are associated with poor glycaemic control (HbA1c $\geq 6.5\%$). Sufficient serum 25OHD levels were also associated with poorer blood glucose control. Further research is needed to investigate an optimal serum concentration or threshold to support adequate blood glucose control.

INTRODUCTION

In 2010, the Centers for Disease Control and Prevention estimated ~25 million individuals in the USA are living with diagnosed diabetes, and another ~7 million people have undiagnosed diabetes.¹ There is expected to be a

What this paper adds

- ▶ Vitamin D is involved in glucose metabolism.
- ▶ Reduce serum vitamin D concentrations are associated with the risk of Type 2 diabetes mellitus.
- ▶ Serum vitamin D concentrations considered to be sufficient are associated with the risk of Type 2 diabetes mellitus

70% increase among adults living with type 2 diabetes mellitus (T2DM) between the years 2010 and 2030.² This exponential rise in prevalence of T2DM poses a public health crisis considering the strain of healthcare costs, burden of disease complications and reduction in quality of life. The ability to identify all potential influences on this looming crisis continues to be vital.

T2DM is a metabolic disorder related to a signalling defect leading to insulin resistance that prevents glucose from entering into the cell.³ The pathophysiology of T2DM differs from type 1 diabetes mellitus (T1DM) in many ways with the primary characteristic of T2DM being insulin resistance, whereas beta cell destruction is the main cause of T1DM.⁴ Glycosylated haemoglobin A1c (HbA1c), reported as a percentage, is an estimation of blood glucose control and considered an acceptable diagnostic method by the American Diabetes Association.⁵ A HbA1c of 6.5% has been established as a threshold value for a diagnosis of T2DM. While many factors influence blood glucose control, the association between poor blood glucose control and micronutrient deficiencies needs to be considered.^{6–8}

Vitamin D has a functional role in maintaining blood glucose homeostasis, although this mechanism is not fully understood.^{9–13} Once metabolised into its active form, vitamin D is involved in several biochemical processes including insulin function and

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Nicolo M, Boullata JI. *bmjnph* 2019;2:35–38.

cellular glucose uptake.^{3 14 15} Vitamin D receptors have been identified in pancreatic tissue including beta cells, although its specific functional role within the pancreas is not clear.^{3 14-17}

Classifying optimal serum 25-hydroxyvitamin D (25OHD) concentrations as the biomarker for vitamin D status continues to be debated. Concentrations of 25 nmol/L (10 ng/mL) or less of calcidiol (25OHD) have been associated with calcium malabsorption increasing the risk of bone disorders and muscle dysfunction, whereas concentrations greater than or equal to 75 nmol/L (30 ng/mL) have been associated with normal function.^{14 17} Inconsistency in 25OHD concentrations used to define deficiency in previous research studies creates a challenge in determining the threshold value for evaluating an association between vitamin D status and risk for T2DM. Few research studies have been designed to assess the relationship among varying levels of serum 25OHD concentrations and measures of blood glucose control among adults in the USA.^{10 13 18 19} Therefore, the primary aim of this study is to describe the relationship between serum 25OHD concentrations and measures of HbA1c percentage in a large cross-sectional sample of adults in the USA, using National Health and Nutrition Examination Survey (NHANES) data from 2003 to 2010. The second aim of this study is to determine whether lower 25OHD concentrations are associated with greater odds of having a HbA1c greater than or equal to 6.5%.

METHODS

Data were obtained using publicly available information from NHANES for 2003 to 2010 (<https://www.cdc.gov/nchs/nhanes/index.htm>). Information regarding laboratory and interview protocols for NHANES data collection has been published elsewhere.²⁰ Participants in this study

included adult men and non-pregnant women 20 years of age and older. The sample was further restricted to include participants with a measured HbA1c% and serum 25OHD concentrations.

Results from previously published research indicate decreased bioavailability of vitamin D among obese individuals.²¹ Significant reduction of serum 25OHD concentrations have been observed with increasing body mass index (BMI); however, this relationship does not appear to be reciprocated (ie, no influence on body fat accumulation).^{22 23} Increased adipose tissue is involved in endocrine disruption of vitamin D disposition resulting in lower circulating 25OHD.^{23 24} Given the strong relationship between obesity and serum 25OHD, we included BMI as a control variable in our analyses. Additionally, we controlled for demographic variables including age, sex and race.

Statistical methods

Continuous variables were reported as mean (SD) and categorical variables as frequency (percentage). Our primary aim was to determine whether 25OHD measures are predictors of HbA1c >6.5%. We conducted binary logistic regression using SPSS V.24, using the continuous variables for serum 25OHD to determine the OR and 95% CI for HbA1c >6.5% while adjusting for sex, race and BMI. Observing a consistent significant association between measures of serum 25OHD and HbA1c across the NHANES cycles, measures of serum 25OHD were grouped into quartiles in order to determine which serum 25OHD measures were at greater odds of having a HbA1c >6.5% compared with greater measures of 25OHD. Quartiles of 25OHD were entered into a binary logistic regression model to determine the OR and 95% CI for HbA1c >6.5% while adjusting for age, sex, race and

Table 1 Descriptive information NHANES 2003 to 2010

Variables	2003 to 2004	2005 to 2006	2007 to 2008	2009 to 2010
Sex N (%)				
Male	2130 (48.4)	2112 (49.9)	2206 (48.8)	2729 (48.2)
Female	2272 (51.6)	2297 (52.1)	2318 (51.2)	2931 (51.8)
Race N (%)				
Mexican American	881 (20)	901 (20.4)	792 (17.5)	1049 (18.5)
Hispanic	134 (3)	136 (3.1)	515 (11.4)	577 (10.2)
Non-Hispanic white	2359 (53.6)	2228 (50.5)	2209 (48.8)	2751 (48.6)
Non-Hispanic black	836 (19)	975 (22.1)	833 (18.4)	968 (17.1)
Other	192 (4.4)	169 (3.8)	175 (3.9)	315 (5.6)
Age (years) M (±SD)	50.4 (19.4)	48.1 (18.7)	50.9 (17.8)	49.3 (17.7)
25OHD (nmol/L) M (±SD)	58.7 (24.0)	57.1 (21.0)	57.5 (24.4)	60.1 (25.8)
HbA1c (%) M (±SD)	5.6 (0.96)	5.6 (1.0)	5.8 (1.0)	5.7 (1.0)
BMI (kg/m ²) M (±SD)	28.4 (6.3)	28.8 (6.8)	29.0 (6.6)	29.2 (6.8)

BMI, body mass index; HbA1c, haemoglobin A1c; NHANES, National Health and Nutrition Examination Survey; 25OHD, 25-hydroxyvitamin D.

Table 2 Binary logistic regression model predictors HbA1c >6.5% NHANES 2003 to 2010

Variable	2003 to 2004 exp (B), 95% CI	2005 to 2006 exp (B), 95% CI	2007 to 2008 exp (B), 95% CI	2009 to 2010 exp (B), 95% CI
25OHD	0.983 (0.978 to 0.987)* 0.980 (0.975 to 0.985)† 0.985 (0.979 to 0.990)‡	0.974 (0.968 to 0.980)* 0.970 (0.964 to 0.976)† 0.976 (0.969 to 0.982)‡	0.986 (0.982 to 0.990)* 0.984 (0.980 to 0.988)† 0.989 (0.984 to 0.993)‡	0.988 (0.985 to 0.992)* 0.984 (0.980 to 0.987)† 0.988 (0.984 to 0.991)‡
BMI	1.069 (1.054 to 1.084)* 1.091 (1.074 to 1.109)† 1.078 (1.061 to 1.096)‡	1.073 (1.059 to 1.088)* 1.092 (1.076 to 1.109)† 1.079 (1.063 to 1.096)‡	1.078 (1.065 to 1.092)* 1.097 (1.083 to 1.112)† 1.089 (1.074 to 1.105)‡	1.078 (1.066 to 1.090)* 1.095 (1.082 to 1.109)† 1.088 (1.074 to 1.101)‡

p<0.0001.

*Univariate model.

†Controlled for age, sex and race.

‡Multivariate model controlled for age, sex, race and BMI.

BMI, body mass index; HbA1c, haemoglobin A1c; NHANES, National Health and Nutrition Examination Survey; 25OHD, 25-hydroxyvitamin D.

BMI. For all analyses, p value <0.05 was considered statistically significant.

RESULTS

Results for descriptive characteristics for each NHANES cycle are presented in table 1. Using binary logistic regression analyses, the odds of having a HbA1c measure of 6.5% or greater was associated with having a greater BMI and lower measure of 25OHD (table 2). This was consistent for each NHANES cycle. When all variables were added into the full model, including sex, race, BMI and 25OHD, the BMI and 25OHD were associated with greater odds of having a HbA1c of 6.5% or greater. Adults with a 25OHD in the lowest quartile have greater odds of having a HbA1c of 6.5% or greater when compared with those in the highest quartile (table 3). Furthermore, the odds of having a HbA1c percentage of 6.5% or greater remained statistically significant for each quartile of 25OHD below the reference.

DISCUSSION

The aim of this study was to describe the relationship between serum concentrations of 25OHD and HbA1c. We observed that lower measures of serum 25OHD were associated with greater HbA1c. Additionally, adults with serum 25OHD concentrations within the lowest quartile had significantly greater odds of having a higher HbA1c% compared with adults with concentrations in the highest quartile. Furthermore, we found that adults with serum 25OHD concentrations within the acceptable or recommended 'sufficient' range of serum 25OHD (30–50 nmol/L) had greater odds of having a HbA1c >6.5%.

The results from the present study coincide with similar studies where greater risk of T2DM was associated with lower serum 25OHD concentrations.^{10 13 25} In

a cross-sectional study of adults 18 years of age and older, an inverse relationship was observed between HbA1c levels and serum 25OHD concentrations.²⁶ Authors of a longitudinal study from Finland reported lower incidence of T2DM among men and women in the highest serum 25OHD quartile compared with the lowest quartile.²⁷ A

Table 3 Quartiles of serum 25OHD in multivariate logistic regression model predictor HbA1c >6.5%

Quartiles serum 25OHD (N, %)	OR (95% CI)
Q1: 0 to 41 nmol/L N=4879 (26.4)	2.60 (2.26 to 3.01)* 3.08 (2.65 to 3.59)† 2.37 (2.03 to 2.77)‡
Q2: 42 to 56 nmol/L N=4879 (26.4)	1.85 (1.58 to 2.16) ^A * 1.97 (1.68 to 2.31) ^{B†} 1.68 (1.56 to 1.61)‡
Q3: 57 to 72 nmol/L N=4430 (24)	1.48 (1.26 to 1.74)* 1.49 (1.27 to 1.75)† 1.37 (1.16 to 1.61)‡
Q4 (reference): 73 to 260 nmol/L N=4472 (24.2)	1

p<0.0001.

*Univariate model.

†Controlled for age, sex and race.

‡Multivariate model controlled for age, sex, race and BMI.

BMI, body mass index; HbA1c, haemoglobin A1c; 25OHD, 25-hydroxyvitamin D.

strength of our study is the large sample size of adults over the age of 20 years living in the USA. Although NHANES is designed to represent individuals living in the USA, it is cross-sectional data including measurements from one time point limiting the generalisability to all populations. We did not account for use of medications to treat diabetes due to a large percentage of missing data. Approximately 2% or less of the sample size for each NHANES cycle reported use of insulin to control their blood glucose. Additionally, >90% of responses regarding use of oral medication for diabetes was missing. We were unable to consider the time of year in which blood samples were collected and analysed due to lack of availability. Neither was supplemental dietary vitamin D.

In conclusion, lower serum 25OHD is associated with poor glycaemic control among adults 20 years and older. Since adults with serum 25OHD levels considered to be sufficient had greater odds of having a HbA1c >6.5%, additional research is needed to determine appropriate threshold serum 25OHD concentrations associated with optimal glucose metabolism.

Contributors MN analysed the data and wrote the manuscript. JIB contributed to manuscript editing, the study design and manuscript revisions. All authors contributed to the critical interpretation of the results, reviewed the manuscript for important intellectual content and approved the final version of the manuscript. MN is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding MN was supported by a grant from the National Institutes of Health, USA (T32CA009492-34).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open-access repository.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Michele Nicolo <http://orcid.org/0000-0002-7492-9440>

REFERENCES

- Control CfD, Prevention. *National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014*. Atlanta, GA: US Department of Health and Human Services 2014, 2014.
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87:4–14.
- Shils ME, Shike M. *Modern nutrition in health and disease*. Lippincott Williams & Wilkins, 2006.
- Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetologia* 2003;46:3–19.
- Saudek CD, Brick JC. The clinical use of hemoglobin A1c. *J Diabetes Sci Technol* 2009;3:629–34.
- Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med* 2001;345:790–7.
- Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006;444:840–6.
- Pasco JA, Nicholson GC, Brennan SL, et al. Prevalence of obesity and the relationship between the body mass index and body fat: cross-sectional, population-based data. *PLoS One* 2012;7:e29580.
- Gupta AK, Brashear MM, Johnson WD. Predisease conditions and serum vitamin D levels in healthy Mexican American adults. *Postgrad Med* 2012;124:136–42.
- Gupta AK, Brashear MM, Johnson WD. Low vitamin D levels, prediabetes and prehypertension in healthy African American adults. *Nutr Metab Cardiovasc Dis* 2012;22:877–82.
- Gupta GK, Agrawal T, Del Core MG, et al. Decreased expression of vitamin D receptors in neointimal lesions following coronary artery angioplasty in atherosclerotic swine. *PLoS One* 2012;7:e42789.
- Abbasi F, Feldman D, Caulfield MP, et al. Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension. *Am J Hypertens* 2015;28:266–72.
- Abbasi F, Blasey C, Feldman D, et al. Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes. *J Nutr* 2015;145:714–9.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96:1911–30.
- Holick MF, deficiency VD. Vitamin D deficiency. *N Engl J Med* 2007;357:266–81.
- Moyad MA. Vitamin D: a rapid review. *Urol Nurs* 2008;28:343–9.
- Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. *Public Health Nutr* 2011;14:938–9.
- Ganji V, Zhang X, Tangpricha V. Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data. *J Nutr* 2012;142:498–507.
- Kositsawat J, Kuchel GA, Tooze JA, et al. Vitamin D insufficiency and abnormal hemoglobin A1c in black and white older persons. *J Gerontol A Biol Sci Med Sci* 2015;70:525–31.
- Mirel L, Mohadjer L, Dohrmann S, et al. National Health and Nutrition Examination Survey: estimation procedures, 2007–2010. Vital and health statistics. *Series 2, Data evaluation and methods research* 2013;159:1–17.
- Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr* 2000;72:690–3.
- Vimalawaran KS, Berry DJ, Lu C, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. *PLoS Med* 2013;10:e1001383.
- Aatsinki S-M, Elkhwanky M-S, Kumm O, et al. Fasting-induced transcription factors repress vitamin D bioactivation, a mechanism for vitamin D deficiency in diabetes. *Diabetes* 2019;68:918–31.
- Bell NH, Greene A, Epstein S, et al. Evidence for alteration of the vitamin D-endocrine system in blacks. *J Clin Invest* 1985;76:470–3.
- Schafer AL, Napoli N, Lui L, et al. Serum 25-hydroxyvitamin D concentration does not independently predict incident diabetes in older women. *Diabet Med* 2014;31:564–9.
- Kositsawat J, Freeman VL, Gerber BS, et al. Association of A1c levels with vitamin D status in U.S. adults: data from the National Health and Nutrition Examination Survey. *Diabetes Care* 2010;33:1236–8.
- Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. *Epidemiology* 2008;19:666–71.